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Abstract
Background: Combined pulmonary fibrosis and emphysema (CPFE) is increasingly acknowledged as a separate
syndrome with distinct clinical, physiological and radiological characteristics. We sought to identify physiologic and
radiographic indices that predict mortality in CPFE.
Methods: Data on clinical characteristics, pulmonary function, high-resolution computed tomography (HRCT) and
treatment were compared between patients with usual interstitial pneumonia (UIP) plus emphysema (CPFE group)
and those with IPF alone (IPF group). Composite physiologic index (CPI) and HRCT scores at diagnosis and during
follow-up were assessed.
Results: CPFE group (N = 87) was characterized by the predominance of males and smokers, who were less likely
to have viral infection prior to the diagnosis, and display basal crackles, finger clubbing and wheeze, as compared
to that in the IPF group (N = 105). HRCT and CPI scores increased over time in both groups. Moreover, CPFE group
had a poorer prognosis, lower 5-year survival rate (43.42 % vs. 65.56 %; P < 0.05), and higher mortality (39.47 % vs.
23.33 %; P < 0.05) as compared to that in the IPF group. All CPFE patients received oxygen therapy, antibiotics and
oral N-acetylcysteine; > 50 % received bronchodilators, 40 % received corticosteroids and 14 % needed noninvasive
mechanical ventilation. On survival analyses, pulmonary arterial hypertension (PAH) and ≥ 5-point increase in CPI
score per year were predictors of mortality in the CPFE group (hazard ratio [HR]: 10.29, 95 % Confidence Interval
[CI]: 2.69–39.42 and HR: 21.60, 95 % CI: 7.28–64.16, respectively).
Conclusion: Patients with CPFE were predominantly male and smokers and exhibited distinct clinical, physiological
and radiographic characteristics. They had a poorer prognosis than IPF. PAH and ≥ 5-point increase in CPI score per
year were predictors of mortality in these patients. Future studies are needed to identify the optimal treatment
approach to CPFE.
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Background
Patients with idiopathic pulmonary fibrosis (IPF) com-
bined with emphysema were first reported several
decades ago [1–3]. In 1990, Wiggins et al. conducted a
retrospective study of eight patients who had high-
resolution computed tomography (HRCT) findings of
co-existing cryptogenic fibrosing alveolitis and emphy-
sema [4]. Recent studies have indicated a more frequent
association of emphysema with IPF than was previously
thought. This study led to the characterization of the
syndrome of combined pulmonary fibrosis and emphy-
sema (CPFE), based on radiographic findings of upper
lobe emphysema, and lower lobe pulmonary fibrosis
(PF). Among the interstitial lung diseases (ILD) with
concomitant emphysema, IPF is the most frequent.
In clinical practice, CPFE cases are not uncommon, and
the estimated prevalence of emphysema is thought to
range between one quarter and one half of all IPF patients
[5, 6]. In the past 10 years, this syndrome has increasingly
been acknowledged as a separate clinical entity. The syn-
drome is characterised by distinct symptomatology, clin-
ical manifestations, radiological and histopathological
features, and prognosis [7, 8]. CPFE is most often ob-
served in males with a mean age of 65–70 years [7, 9–12].
Clinical features include severe dyspnea on exertion,
subnormal spirometry findings, severely impaired gas ex-
change, hypoxemia on exercise, and characteristic findings
on imaging [9, 11, 12]. More importantly, CPFE has a dis-
mal prognosis with a 5-year survival rate of 55 % [9].
CPFE is associated with higher mortality and lower me-
dian survival time (25 months) as compared to IPF
(34 months) [6]. Pulmonary arterial hypertension (PAH) is
known to develop in up to half of all patients with CPFE,
and has been identified as a key determinant of prognosis
[6, 9]. A few studies have suggested pulmonary function
parameters and the composite physiologic index (CPI) as
being predictors of CPFE prognosis [5]. However, the
prognostic value of quantitative physiologic and imaging
characteristics has not been adequately investigated.
Finally, the therapeutic options for patients with CPFE are
limited, and there are no consensus recommendations for
treatment of emphysema in the setting of IPF.
In this study, we retrospectively compared the clinical
and radiographic characteristics, available therapeutic op-
tions, and prognostic indicators between patients with
CPFE and those with IPF alone. Furthermore, we assessed
the prognostic significance of quantitative physiologic and
radiographic indices in patients with CPFE.
Methods
Subjects
Subjects were genetically unrelated ethnic Northern Han
Chinese and from Heilongjiang and Harbin Province. All
hospitalized patients were consecutively recruited from
January 2001 to December 2013 in the Department of
Respiratory Medicine at the First Affiliated Hospital of
Harbin Medical University. We included two groups: pa-
tients with CPFE who had usual interstitial pneumonia
(UIP) pattern according to HRCT, and patients with IPF
alone. The patients in the CPFE group met the diagnos-
tic criteria for IPF for patients not subjected to surgical
lung biopsy (in accordance with the 2011 American
Thoracic Society and European Respiratory Society
(ATS/ERS) statement) [13]. Additionally, they had a
chest HRCT scan showing co-existing emphysema and
PF, well-demarcated areas of decreased attenuation de-
lineated by a very thin (<1 mm) or no wall, multiple
bullae (>1 cm) with upper zone predominance, reticular
abnormalities with subpleural and basal predominance,
honeycombing, architectural distortion, traction bron-
chiectasis, and/or ground-glass opacities, and/or areas of
alveolar consolidation [9]. Patients diagnosed with con-
ditions that are known to cause PF such as drug-induced
interstitial lung disease, pneumoconiosis, hypersensitivity
pneumonitis, sarcoidosis, pulmonary histiocytosis, lym-
phangioleiomyomatosis and eosinophilic pneumonia,
were excluded from the study. In addition, PAH de-
scribes a subpopulation of patients with Pulmonary
hypertension (PH) characterized hemodynamically by the
presence of pre-capillary PH including an end-expiratory
pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg
and a pulmonary vascular resistance > 3 Wood units [14].
Methods
Medical records, pulmonary function tests and HRCT
scans at diagnosis and during the 60-month follow-up
period, were analyzed. The composite physiologic
index (CPI) that represents a combination of pulmon-
ary ventilation and diffusing capacity, and chest
HRCT score were obtained to evaluate the extent of
disease at diagnosis and at 6 months intervals up to a
total of 36 months. The formula for the CPI is as fol-
lows: CPI = 91.0−(0.65 × percent predicted diffusing
capacity for carbon monoxide-DLCO])−(0.53 × percent
predicted forced vital capacity [FVC]) + (0.34 × per-
centage of predicted forced expiratory volume in 1 s
[FEV1]) [15].
HRCT scans were evaluated separately by two radiolo-
gists using an image-processing program (ImageJ, version
Windows 32-bit 1.6.0_24, a public program available at
(https://imagej.nih.gov/ij/download.html). The extent of
emphysema was visually estimated bilaterally in HRCT
sections at three anatomic levels: near the superior margin
of the aortic arch (the upper lung field), the carina (the
middle lung field), and at 1 cm above the right hemidiaph-
ragm (the inferior lung field). A score was assigned to
grade the emphysematous changes in each lung field as
follows: score 0 (no emphysema), score 0.5 (trivial, < 5 %),
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score 1 (mild, 5–25 %), score 2 (moderate, 26–50 %), score
3 (marked, 51–75 %), and score 4 (severe, > 75 %). The
severity of emphysema was graded based on the sum of
the scores in all six lung fields as follows: score 0 (no em-
physema), score 1–8 (mild); score 9–16 (moderate), score
17–24 (severe) [16]. PF was assessed in HRCT sections at
three anatomic levels. The extent of fibrosis was quanti-
fied as percent lung parenchyma affected at each section,
as well as the cumulative involved lung by ground glass
opacities, interlobular septal thickening, reticular opaci-
ties, and honeycombing, respectively, according to the
following scoring system: score 0 (not affected), score 1
(≤5 %), score 2 (6–24 %), score 3 (25–49 %), score 4 (50–
74 %), score 5 (≥75 %) [17]. PF score was adjusted by
multiplying the coefficient 4.8, which allowed the severity
of fibrosis to be graded similar to that of emphysema [18].
The final HRCT score for CPFE was the sum of emphy-
sema score and fibrosis score.
The study endpoint was the completion of the 60-
month follow-up, including all-cause deaths and loss to
follow-up. Mortality of CPFE was calculated from the
deaths that directly resulted from CPFE or CPFE-related
causes.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD); intergroup differences were assessed by
performing t-test. Intragroup variability was assessed by
repeated Analysis of Variance (ANOVA). Categorical
variables are presented as percentages and compared
using the chi-square test and Fisher’s exact test.
Univariate and multivariate survival analyses were
performed to determine the relationship between clin-
ical parameters, physiological indices, HRCT imaging
scores and survival. Differences with an associated P value
of < 0.05 were considered significant. All statistical ana-
lyses were performed using SAS version 9.1.3 software.
Results
Clinical characteristics and outcomes
A total of 87 patients were included in the CPFE group
(79 males; 69 ± 8.5 years). The IPF group included 105
patients (66 males; 60 ± 4.3 years). The demographic,
clinical characteristics and outcomes in both the groups
are presented in Table 1.
The mean age at diagnosis, and the proportion of
males and smokers in the CPFE was higher than that in
the IPF (P < 0.05 for all). Patients with CPFE had less
frequent history of viral infection as compared to that in
the IPF group (P < 0.05). CPFE patients were more likely
to have concomitant cardiovascular and cerebrovascular
diseases than IPF patients (P < 0.05). CPFE patients more
frequently presented with wheeze (63.2 % vs. 11.4 %,
respectively), and less frequently with basal crackles,
than IPF patients (P < 0.05 for both). These were more
likely to show concomitant cardiovascular and cerebro-
vascular disease, wheeze (63.2 % vs. 11.4 %), and an
increased level of carcinoembryonic antigen (CEA) as
Table 1 Demographic variables, clinical characteristics and








Age, years 66 ± 8.5 60 ± 4.3 0.63 <0.0001*
Male 76 66 14.83 0.0001
BMI < 18 kg/m2 37 39 0.58 0.4475
Smokers 75 44 39.63 <0.0001
History of viral infection 13 37 10.18 0.0014
Diabetes 16 10 3.19 0.0739
Cardiovascular and
cerebrovascular diseases
67 63 6.29 0.0121
Cancer 8 8 0.15 0.694
Cor pulmonale 21 25 0.01 0.9577
PAH 39 45 0.08 0.7841
Finger clubbing 13 11 0.87 0.3516
Wheeze 55 12 56.17 <0.0001
Basal crackles 47 97 37.34 <0.0001
CEA increasing 21 6 49.11 <0.0001















Data presented as N (%) or mean ± standard deviation (range); Chi-square test
was performed for assessing statistical significance, unless indicated otherwise
Abbreviations: CEA carcinoembryonic antigen, PAH pulmonary arterial hypertension
*Age compared by t-test
Table 2 Mean CPI scores by study group during follow-up
Group 0 month 6 months 12 months 18 months 24 months 30 months 36 months
IPF 43.76 ± 8.74 44.68 ± 8.67 45.93 ± 8.58 47.14 ± 8.53 48.67 ± 8.5 50.78 ± 8.49 53.36 ± 8.48
CPFE* 45.04 ± 8.17 46.45 ± 7.78 49.56 ± 7.91 52.96 ± 8.19 56.4 ± 9.22 60.6 ± 9.51 65.55 ± 10.26
Data are presented as mean ± Standard Deviation
Abbreviations: CPI composite physiologic index, IPF idiopathic pulmonary fibrosis, CPFE combined pulmonary fibrosis and emphysema
*P < 0.05 compared to the changes in IPF group
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compared to patients in the IPF group (P < 0.05). There
was no significant difference in the proportion of
patients with BMI < 18 kg/m2 between the two groups
(P > 0.05). At the completion of the 60-month follow-up
period, 33 patients with CPFE were alive; 11 were lost to
follow-up; 30 died from CPFE or CPFE-related causes
(lung cancer excluded); 11 died from extrapulmonary
diseases, and 2 died from lung cancer. The mean 5-year
survival rate in the CPFE group was 43.42 %, with an
all-cause mortality rate of 56.58 %, and CPFE-related
mortality of 39.47 %. By comparison, 59 IPF patients
were alive at the end of 60 months, 15 were lost to
follow-up; 21 died from IPF or IPF-related causes, 18
from extrapulmonary diseases and 2 from lung can-
cer. The mean 5-year survival rate of IPF patients
was 65.56 %, with a mean all-cause mortality rate of
34.44 %, and IPF-related mortality of 23.33 %. Com-
pared to IPF, CPFE had a significantly lower 5-year
survival rate, higher all-cause mortality and disease-
related mortality (P < 0.05).
Longitudinal analyses of quantitative physiologic and
radiographic
The CPI and HRCT scores were used to evaluate the
disease progression in both groups and were recorded at
6-month intervals for a total duration of 36 months.
During follow-up, all-cause deaths were included in the
analysis, whereas data pertaining to patients who were
lost to follow-up were excluded. A total of 80 CPFE and
99 IPF completed the follow-up with complete data
available for analyses (Tables 2 and 3; Figs. 1 and 2).
The CPIs of patients with CPFE were significantly
higher than those of patients with IPF at all time
points during the course of the disease (P < 0.05)
(Table 2). As shown in Fig. 1, the CPI score of the
CPFE increased more dramatically as compared to
that in the IPF group over the 36 months of follow-
up, which suggests a more rapidly progressive clinical
course of CPFE as compared to that of IPF. The same
tendency was observed with respect to HRCT scores
(P < 0.05).
Table 3 Mean HRCT scores by study group during follow-up
Group 0 month 6 months 12 months 18 months 24 months 30 months 36 months
IPF 28.79 ± 3.12 30.34 ± 3.02 31.67 ± 3.01 33.36 ± 2.83 35.51 ± 3.04 37.35 ± 3.15 39.46 ± 2.88
CPFE* 31.32 ± 5.07 32.16 ± 5.08 33.7 ± 5.05 35.68 ± 5.13 38.09 ± 5.41 40.7 ± 5.25 43.21 ± 4.68
Data are presented as mean ± Standard Deviation
Abbreviations: HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis, CPFE combined pulmonary fibrosis and emphysema
*P < 0.05 compared to the changes in IPF group
Fig. 1 Longitudinal trend of mean CPI scores by study group during
follow-up. CPI, Composite physiologic index; IPF, Idiopathic pulmonary
fibrosis; CPFE, Combined pulmonary fibrosis and emphysema
Fig. 2 Longitudinal trends of mean HRCT scores by study group. HRCT,
High-resolution computed tomography; IPF, Idiopathic pulmonary
fibrosis; CPFE, Combined pulmonary fibrosis and emphysema
Zhang et al. BMC Pulmonary Medicine  (2016) 16:137 Page 4 of 8
Treatment
The effect of various therapeutic regimens on prognosis
of CPFE patients were assessed by CPI and HRCT scores
in sub-groups of patients receiving different treatment.
All 87 patients with CPFE received oxygen therapy, anti-
biotics and oral N-acetylcysteine treatment. Out of these,
12 patients who experienced acute exacerbation or re-
spiratory failure during the disease course were adminis-
tered noninvasive mechanical ventilatory support; 36
received bronchodilators plus corticosteroids and 15 re-
ceived bronchodilators but no corticosteroids. The treat-
ment lasted for at least 2 months per year. Rare cases
that received other treatments such as immunosuppres-
sants and anti-fibrotic targeted therapy were excluded
from the analyses. At the end of the 36-month follow-
up, complete data on the CPIs and HRCT scores were
available for 69 patients in the CPFE group. These were
divided into four sub-groups based on the treatment
regimen (Tables 4 and 5). As shown in Table 4, signifi-
cant differences were observed with respect to the CPIs
in the different treatment groups at each time point of
follow-up (F = 9.73; P < 0.0001). The rate of increase in
CPI scores showed significant differences between the
four different treatment groups, as well as the inter-
action effects of different time points during follow-up
(F = 24.31; P < 0.0001). The rate of increase in CPI score
in the group treated with oxygen therapy, bronchodila-
tors and corticosteroids was lower than that in the other
groups, which suggests that this therapeutic regimen
may be more effective, especially if administered within
24 months from diagnosis (Fig. 3). In contrast, patients
on mechanical ventilation support deteriorated dramat-
ically with an abrupt increase in CPI score. Significant
differences in HRCT scores were also observed among
the different treatment groups at each time point of
follow-up, as well as with respect to the interaction
effects at different time points (F = 3.3882, P = 0.02182;
F = 14.9756, P < 0.0001). The trend of HRCT and CPI
among different treatment groups is shown in Fig. 4.
Survival analyses
Univariate and multivariate survival analyses were
performed to identify the clinical parameters associated
with mortality in CPFE (Table 6). After adjusting for po-
tential confounders, PAH and a ≥ 5-point increase in
CPI per year retained its statistical significance (Table 7).
PAH patients had 10.29 times increased risk of death as
compared to patients without PAH. The rate of increase
in CPI by > 5 scores per year was associated with a 21.6
times higher risk of death.
Discussion
Evidence suggests that a syndrome of CPFE, most
frequently associated with IPF, deserves to be recog-
nized as a separate clinical entity owing to the dis-
tinct clinical, functional, radiological, and pathological
characteristics. In the present study, we compared the
clinical characteristics, quantitative respiratory physio-
logical index, radiographic scoring system, treatment
and prognosis between patients with UIP plus emphy-
sema (CPFE group) and IPF alone.
Table 4 Mean CPI scores in CPFE group disaggregated by therapeutic regimen on follow-up
Group 0 month 6 months 12 months 18 months 24 months 30 months 36 months
O 47.23 ± 7.98 47.24 ± 7.4 51.35 ± 7.55 55.68 ± 6.19 60.06 ± 6.28 64.86 ± 6.24 70.2 ± 6.39
M 43.55 ± 8.82 48.5 ± 7.79 53.41 ± 7.35 59.72 ± 7.41 63.22 ± 11.99 70.83 ± 7.87 78.22 ± 7.22
O + B + C* 43.79 ± 8.08 45.1 ± 7.83 46.65 ± 7.36 48.32 ± 7.52 50.45 ± 7.12 53.19 ± 6.96 56.96 ± 6.88
O + B 45.71 ± 8.14 46.77 ± 8.45 50.62 ± 8.48 54.37 ± 7.46 59.36 ± 7.35 63.36 ± 7.21 68.59 ± 6.76
Data presented as mean ± standard deviation
Abbreviations: CPI composite physiologic index, CPFE combined pulmonary fibrosis and emphysema, O oxygen therapy, M mechanical ventilation, B
bronchodilators, C corticosteroids
*P < 0.05 compared to changes in O group
Table 5 Mean chest HRCT scores in CPFE patients disaggregated by therapeutic regimen on follow-up
Group 0 month 6 months 12 months 18 months 24 months 30 months 36 months
O 31.33 ± 4.62 31.61 ± 4.47 32.83 ± 4.69 34.11 ± 4.85 35.69 ± 5.01 37.92 ± 4.94 40.67 ± 5.08
M 32.4 ± 3.92 33.13 ± 4.49 34.53 ± 4.53 36.33 ± 4.7 38.4 ± 4.75 40.67 ± 4.37 43.33 ± 3.22
O + B + C* 30.38 ± 6.02 31.67 ± 6.12 33.46 ± 5.93 36.04 ± 5.76 38.96 ± 5.69 41.96 ± 4.65 44.83 ± 3.71
O + B 31.83 ± 5.84 33.58 ± 5.42 35.75 ± 4.59 38.83 ± 3.64 43.17 ± 2.08 46.58 ± 1.16 47.42 ± 0.79
Data presented as mean ± SD
Abbreviations: HRCT high-resolution computed tomography, O oxygen therapy, M mechanical ventilation, B bronchodilators C corticosteroids
*P < 0.05 compared to the changes in O group
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Although controversies exist in the published litera-
ture mainly regarding the prognosis of CPFE patients,
the clinical characteristics of CPFE remain consistent
with those described by Cottin et al. [9]. Most of the pa-
tients in the CPFE group in our study were males with a
mean age between 65 and 70 years and had a smoking
history which suggests tobacco smoking as a potential
etiological factor for CPFE [7]. Perhaps the lower sur-
vival in CPFE group than IPF group might be partially
explained by the difference in proportion of smokers in
the two groups. Compared to patients with IPF, those
with CPFE had a less frequent history of viral infection
prior to the diagnosis, which suggests that viral infection
may not be a risk factor for CPFE; the increasing trend
in CEA with time; and basal crackles were more
frequently observed on physical examination along with
presence of finger clubbing. Surprisingly, over half of
CPFE presented with wheeze, which was significantly
more than that in patients with IPF alone. This suggests
that airway spasm may be more common in CPFE,
which might aggravate hypoxia concomitantly with
hypercapnia. This pathophysiological change may cause
extrapulmonary tissue damage and have an adverse ef-
fect on prognosis; therefore, CPFE may be considered as
a more severe interstitial lung disease than IPF.
In this study, the chest HRCT and CPI scores were
used for the first time to assess and monitor the course
of CPFE. Simultaneous review of these two quantitative
indices allowed for an objective evaluation of pulmonary
structural and functional damage over the follow-up
period. HRCT score and CPI tended to increase over
time in both CPFE and IPF groups. However, the clinical
course of CPFE varied from that of IPF. The increase in
HRCT scores and CPI was more dramatic in the CPFE
group, which suggested a correlation of these two indi-
ces with clinical deterioration of CPFE. These findings
appear to justify the categorization of CPFE as a distinct
syndrome that is characterized by a much worse progno-
sis than that of IPF. Survival analyses showed lower 5-
year survival rate and poorer prognosis compared to IPF
patients (43.42 % vs. 65.56 %; P < 0.05) and a higher
mortality (39.47 % vs. 23.33 %; P < 0.05). However, evi-
dence from recent studies that have compared the prog-
nosis of CPFE with that of PF alone has largely been
equivocal [6, 19, 20]. Cottin et al. reported a 5-year sur-
vival rate of 54.6 % among CPFE patients, which was
higher than that observed in our study, but is still lower
than that of the IPF group [9]. Mejla et al. reported one
IPF group of 110 patients [6]. Of those, 31 (28 %) patients
with CPFE had a higher mortality than that observed in
IPF patients who did not have co-existing emphysema
(median survival time: 25 vs. 34 months, P < 0.01). In con-
trast, others have reported either a better survival associ-
ated with CPFE as compared to that associated with IPF
alone [12], or, no difference in mortality between the
CPFE and IPF groups [20]. These conflicting results may
be attributable to the selection of patients. Since consen-
sus diagnostic criteria for CPFE have not yet been formally
established, some studies included patients with interstitial
lung diseases other than IPF, such as, nonspecific intersti-
tial pneumonia (NSIP) which has a better prognosis than
IPF. Additionally, the outcomes of CPFE may be influ-
enced by the extent of PF associated with IPF, and which
may take several clinical forms depending on the rate of
progression to death [21].
Currently, there is a lack of consensus on the specific
treatment strategy for CPFE. Studies evaluating thera-
peutic options for CPFE patients are still lacking. A few
retrospective studies have reviewed the current treat-
ment strategies for CPFE patients. Treatment has largely
centered on the management of two separate compo-
nents of CPFE: oral corticosteroids, immunosuppressive
Fig. 3 Longitudinal trends of mean CPI scores in CPFE patients
disaggregated by therapeutic regimen. CPI, Composite physiologic
index; CPFE, Combined pulmonary fibrosis and emphysema; O:
Oxygen therapy; M: mechanical ventilation; B: bronchodilators;
C: corticosteroids
Fig. 4 Longitudinal trend of mean chest HRCT scores in CPFE patients
disaggregated by therapeutic regimen. HRCT, High-resolution computed
tomography; CPFE, Combined pulmonary fibrosis and emphysema
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agents, N-acetylcysteine for PF and inhaled bronchodila-
tors for emphysema, often supplemented with long-term
oxygen therapy [7, 9]. Still, antifibrotic drugs used for
patients with IPF may also be effective in those with pul-
monary fibrosis (UIP) and emphysema. Owing to the
retrospective nature of the present study, the effect of
treatment on clinical outcomes of CPFE could not be
evaluated. All 105 patients with IPF received oxygen
therapy and corticosteroids treatment. Out of these, 15
patients who experienced acute exacerbation or respira-
tory failure during the disease course were administered
noninvasive mechanical ventilatory support. Compared
with CPFE group, bronchodilator treatment was not
employed in IPF group. Therefore, the effect resulting
from different treatments was likely to be very limited.
Univariate and multivariate survival analyses revealed
PAH and a > 5-point increase in CPI score per year as
predictors of mortality in CPFE. The risk of development
of PH in CPFE patients was higher than those with IPF
alone. Further, PH in CPFE patients was associated with
an increased risk of death [6, 9, 22, 23]. Consistent with
previous studies, PAH developed in nearly half of all pa-
tients in our CPFE group, and was a key determinant of
mortality in this group (HR: 10.29, 95 % CI: 2.69–39.42).
The development of PAH in CPFE may be attributed to
the synergistic effect of PF and emphysema. In 2003,
Wells et al. derived a composite physiologic index (CPI)
from a group of IPF patients by fitting pulmonary func-
tion tests against disease extent as assessed on CT to
correct the mortality risk assessment of IPF for the con-
founding effect of emphysema [15]. The CPI is simple to
calculate based on the percent of predicted DLCO, FVC
and FEV1, and is also a stronger predictor of mortality
than the single index of pulmonary function [5, 13]. Our
study suggests that a ≥ 5-point increase in CPI per year
can be used as a predictor of mortality in CPFE patients
(HR: 21.60, 95 % CI: 7.28–64.16), with the added advan-
tage of being a non-invasive and easily obtainable
physiological measure of prognosis.
Some limitations of our study are worth noting. Firstly,
this study was a single-center retrospective study which
precluded assessment of the effect of different therapeutic
options on the outcomes of CPFE. Secondly, the possibil-
ity of selection bias cannot be ruled out since not all
eligible subjects had complete radiographic and pulmon-
ary function data available for analyses. Additionally, in
the CPFE group, we only included patients who met the
diagnostic criteria for IPF. CPFE represents a syndrome
that has a characteristic clinical presentation, physiologic
and radiographic findings, but also, possibly, pathological
heterogeneity other than just IPF [9, 19]. Despite these
limitations, the CPFE group in our study was reasonably
well described, and characterized by typical findings.
Conclusion
CPFE, a separate clinical syndrome that occurs predom-
inantly in males and tobacco smokers, is characterized
by distinct clinical, physiologic and radiographic fea-
tures. The longitudinal trend of CPI and HRCT scores
may mirror the clinical course of CPFE. CPFE has a
more dismal prognosis compared to IPF alone. In this
study, PAH and a 5-point increase in CPI per year were
key predictors of mortality in patients with CPFE. Future
prospective studies are needed to identify the optimal
therapeutic approach to CPFE.
Quick look
Current knowledge
Combined pulmonary fibrosis and emphysema (CPFE) is
increasingly acknowledged as a distinct syndrome with
typical clinical, physiological and radiological characteris-
tics. In clinical practice, CPFE cases are not uncommon.
But the therapeutic and treatment options for patients
with CPFE are limited.
Table 6 Univariate analysis: Relationship between clinical
parameters and mortality in CPFE patients
Variable P Hazard ratio 95 % CI
BMI < 18 kg/m2 <0.01 5.64 2.68–11.89
Smoking 0.04 4.18 1–17.47




Corpulmonale <0.01 10.71 5.08–22.59
PAH <0.01 27.68 8.35–91.81
Finger clubbing <0.01 13.91 6.28–30.83
Increasing CEA level <0.01 13.17 6.41–27.11
≥5-point increase of CPI per year <0.01 45.03 15.19–133.52
≥5-score increase of HRCT per year <0.01 4.63 2.47–8.71
Abbreviations: CPFE combined pulmonary fibrosis and emphysema, BMI body
mass index, PAH pulmonary arterial hypertension, CEA carcinoembryonic
antigen, CPI composite physiologic index, HRCT high-resolution computed
tomography, CI confidence interval
Table 7 Multivariate analysis: Relationship between clinical parameters and mortality in CPFE patients
Variable Estimated value Standard error Chi-square value P Hazard ratio 95 % CI
PAH 2.33 0.68 11.57 <0.01 10.29 2.69-39.42
≥5-point increase in CPI score per year 3.07 0.55 30.63 <0.01 21.60 7.28-64.16
Abbreviations: CPFE combined pulmonary fibrosis and emphysema, PAH pulmonary arterial hypertension, CPI composite physiologic index, CI confidence interval
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What this paper contributes to our knowledge
CPFE patients were predominantly male and smokers and
exhibited distinct clinical, physiological and radiographic
characteristics. They had a poorer prognosis than patients
with idiopathic pulmonary fibrosis alone (IPF). Pulmonary
arterial hypertension and ≥ 5-point increase in composite
physiologic index (CPI) score per year were predictors of
mortality in CPFE patients.
Abbreviations
CPFE: Combined pulmonary fibrosis and emphysema; CPI: Composite
physiologic index; CT: Computed tomography; HRCT: High-resolution computed
tomography; ILD: Interstitial lung diseases; IPF: Idiopathic pulmonary fibrosis;
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